NAJIT TECHNOLOGIES, INC.

Beaverton, OR · Biotech · Private

HydroVax platform: hydrogen peroxide-based site-directed oxidation technology for producing inactivated virus vaccines with preserved protective epitopes

Grants
$9.3M
10 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
3
0 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Development of a novel platform to enhance intracellular bioavailability of antisense morpholino oligomers$318,591
Federal grantDepartment of Health and Human Services · Phase II · Development of an H2O2-inactivated chikungunya virus vaccine$2,983,602
Federal grantDepartment of Health and Human Services · Phase II · Development of a Yellow Fever Vaccine for a Vulnerable Population$1,248,114
Federal grantDepartment of Health and Human Services · Phase II · Development of an H2O2-inactivated chikungunya virus vaccine$994,841
Federal grantDepartment of Health and Human Services · Phase II · Development of a Yellow Fever Vaccine for a Vulnerable Population$996,895
Federal grantDepartment of Health and Human Services · Phase II · Development of an H2O2-inactivated chikungunya virus vaccine$989,109
Federal grant· 1 of 2 same dayDepartment of Health and Human Services · Phase I · Optimization of vaccine antigen for the development of improved influenza$224,171
Federal grant· 2 of 2 same dayDepartment of Health and Human Services · Phase I · Optimization of vaccine antigen for the development of improved influenza$224,171
Federal grantDepartment of Health and Human Services · Phase II · Development of a Yellow Fever Vaccine for a Vulnerable Population$997,494
Federal grantDepartment of Health and Human Services · Phase I · Development of an improved intranasal vaccine against influenza$275,107
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3200TheraCea Pharma LC——
3201SAHANE BIOTECH INC——
3202HISTONE THERAPEUTICS——
3203NAJIT TECHNOLOGIES, INC.——
3204OM THERAPEUTICS INC.——
3205Anaveon——
3206IMETABOLIC BIOPHARMA CORPORATION——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 3
  • Multivalent Pan-influenza Vaccineapplication
  • Inactivating Pathogens And Producing Highly Immunogenic Inactivated Vaccines Using A Dual Oxidation Processapplication
  • Inorganic Polyatomic Oxyanions For Protecting Against Antigenic Damage During Pathogen Inactivation For Vaccine Productionapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.